证券代码：002004 证券简称：华邦健康 编号：20210831 | --- | --- | --- | |------------|---------------------------|------------------------------------------------------------| | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | 系活动类 | 媒体采访 | 业绩说明会 | | 别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 参与单位 | | 西南证券杜向阳、阮雯，西南证投部张锴，长盛基金张伟光，新华 | | 名称及人 | | 基金张霖，国开证券周成娟，国都自营王义，博永投资陈亮，汇盛 | | 员姓名 | 建投梁露，穿石投资王俊 | | | 时间 2021 | 年 8 月 31 日 | 13:30-14:00 | | 地点 | 电话会议（西南证券组织） | | | 上市公司 | 董事兼总经理：张海安 | | | 接待人员 | 董事兼董事会秘书：彭云辉 | | | 姓名 | 董事会办公室主任：胡菁菁 | | | | ...

证券代码：002004 证券简称：华邦健康 编号：20210906 | --- | --- | --- | --- | --- | |------------|-------------------------------|------------------------------------------------------------|------------------------|------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中银证券邓周宇、周海涛，上银基金卢扬，中国人寿张树声，远惟 | | | | 名称及人 | | 投资张翠双，鼎晖投资彦婕，安信基金徐衍鹏，惠正投资易建军， | | | | 员姓名 | 阳来军 | 中国人保资管田垒，顺沣资产邓永明，百毅资本闫小龙，大成基金 | | | | | | | | | | 时间 2021 | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20210929 | --- | --- | --- | --- | --- | |-------------|------------------------------------|--------------------------------------------------------------|-------|--------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中金公司张一弛、李千翊，趣时资产王晓东，东方红资产杨仁眉、 | | | | 名称及人 | | 孙梦瑶，上投摩根蔡云翔，高毅资产刘慧敏，景领投资张轶伦，德 | | | | 员姓名 | 福资本裴彦春，德瑞恒丰何小华、方清 | | | | | 时间 | 2021 年 9 月 29 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211122 | --- | --- | --- | --- | --- | |---------------|---------------------------------|--------------------------------------------------------|------------------|----------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 东吴基金、鑫元基金、博煊资产、沣京资本 | | | | 名称及人 | | | | | | 员姓名 | | | | | | 时间 2021 | 年 11 月 22 日 | 16:00-16:40 | | | | 地点 电话会议 | | | | | | | | | | | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211209 | --- | --- | --- | --- | --- | |---------------|----------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------| | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 其他（线上电话会议） | | | | | 参与单位 | | | 中银证券、交银施罗德基金、建信基金、富国基金、华夏久盈、华 | | | 名称及人 | 宝信托 | | | | | 员姓名 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211101 | --- | --- | --- | --- | --- | |-------------------|-------------------------------------|------------------------------------------------------------|----------------------------|-------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中银证券邓周宇、杨志威、梁端玉，交银施罗德基金、重阳投资胡 | | | | 名称及人 | | 敏、兴业基金代鹏举、尚石投资贾鹏飞、德睿恒丰江昕、合正普惠 | | | | 员姓名 | | 投资原芳、南银理财钱晟、汇华理财张昕 | | | | 时间 20 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211129 | --- | --- | --- | --- | --- | --- | --- | |----------|------------------------------------------------|----------------------------------------|-------------------------|-------|---------------------------------------------------------------|-------| | | | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | | | 别 | 新闻发布会 | 路演活动 | | | | | | | 现场参观 | | | | | | | | 其他（线上电话会议） | | | | | | | 参与单位 | | 线下调研：中信证券、银河证券、淳阳基金 | | | | | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20220107 | --- | --- | --- | --- | |------------|--------------------------------------------------------------|---------------------------------------------------------|-------| | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | 系活动类 | 媒体采访 | 业绩说明会 | | | 别 | 新闻发布会 | 路演活动 | | | | 现场参观 | | | | | 其他（线上电话会议） | | | | 参与单位 | 工银瑞信基金 | | | | 名称及人 | | | | | 员姓名 | | | | | 时间 2022 | 年 1 月 7 日 | 9:30-12:00 | | | | 地点 公司会议室、重庆北部宽仁医院 | | | | 上市公司 | 董事、董事会秘书：彭云辉 | | | | 接待人员 | 投资者关系 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥3,481,328,298.92, representing a 20.80% increase year-over-year[4] - Net profit attributable to shareholders decreased by 6.21% to ¥157,107,051.58 for the quarter, while year-to-date net profit increased by 37.73% to ¥717,022,611.56[4] - The net profit for the current period reached ¥1,342,581,873.08, a significant increase from ¥715,999,282.39 in the previous period, representing an increase of approximately 87.2%[28] - Operating profit for the current period was ¥1,818,006,436.61, compared to ¥923,649,475.63 in the previous period, indicating an increase of about 96.8%[28] - Total operating revenue for the current period reached ¥10,180,991,733.93, an increase of 17.98% compared to ¥8,629,345,347.58 in the previous period[25] - The company reported a total comprehensive income of ¥1,553,326,463.12, compared to ¥721,527,099.20 in the previous period, which is an increase of approximately 115.5%[28] - Earnings per share (EPS) for the current period was ¥0.3621, up from ¥0.2629 in the previous period, representing an increase of about 37.8%[28] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥1,888,672,141.44, showing a significant increase of 136.41% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥1,888,672,141.44, compared to ¥798,903,991.74 in the previous period, marking an increase of about 136.4%[31] - The cash inflow from investment activities totaled ¥6,399,652,310.89, compared to ¥5,983,905,914.21 in the previous period, indicating an increase of approximately 6.9%[31] - The company’s cash outflow from investment activities was ¥6,423,466,215.24, slightly higher than ¥6,166,690,319.17 in the previous period, reflecting an increase of about 4.2%[31] - The net increase in cash and cash equivalents was $1,017,905,834.60, significantly higher than $427,130,522.60 previously[34] - The ending balance of cash and cash equivalents reached $3,520,862,118.20, up from $2,643,608,645.75[34] Assets and Liabilities - The total assets of the company as of the end of the reporting period were ¥30,852,486,707.32, reflecting a 2.69% increase from the end of the previous year[7] - Total assets increased to ¥30,852,486,707.32, compared to ¥30,044,426,750.47 in the previous period, marking a growth of 2.68%[24] - Total liabilities decreased slightly to ¥14,059,741,767.02 from ¥14,220,677,628.50, a reduction of 1.13%[24] - The equity attributable to shareholders of the parent company rose to ¥10,476,928,031.26, up from ¥10,109,391,327.10, indicating a growth of 3.63%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 87,819, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71% of shares[13] - The total number of shares held by the top ten shareholders includes 370,449,804 shares held by Tibet Huibang Technology Co., Ltd., which is the only shareholder with over 10% ownership[13] - The company has a total of 30 million shares held by Jiang Xueping, with no shares pledged[17] Operational Metrics - Total operating costs amounted to ¥8,815,184,892.05, up 10.31% from ¥7,993,861,821.86 in the prior period[25] - Research and development expenses increased to ¥286,550,552.75, reflecting a rise of 29.15% from ¥221,884,196.23 year-over-year[25] - The company experienced a significant increase in accounts receivable, which rose by 95.05% to ¥186,284,511.53, mainly due to an increase in bank acceptance bills received during the reporting period[9] - The company reported trading financial assets of approximately ¥753.37 million, down from ¥1.03 billion, representing a decrease of about 27%[18] Strategic Outlook - The company has not disclosed any new product developments or market expansion strategies in the current report[20] - There are no significant mergers or acquisitions reported in the current quarter[20] - The company is focusing on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[27] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[28]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 6,699,663,435.01, representing a 16.57% increase compared to CNY 5,747,430,593.16 in the same period last year[29]. - Net profit attributable to shareholders was CNY 559,915,559.98, a 58.58% increase from CNY 353,089,837.24 year-on-year[29]. - The net profit after deducting non-recurring gains and losses was CNY 557,705,491.22, up 65.40% from CNY 337,195,539.53 in the previous year[29]. - Basic earnings per share increased to CNY 0.2828, reflecting a growth of 58.61% compared to CNY 0.1783 in the same period last year[29]. - The company reported a net cash flow from operating activities of CNY 541,238,737.12, which is a decrease of 3.72% compared to CNY 562,123,622.46 in the same period last year[29]. - The weighted average return on net assets was 5.38%, an increase of 1.72% from 3.66% in the previous year[29]. - The cost of goods sold was ¥4,052,860,818.88, which is an 18.34% increase from ¥3,424,834,627.45 in the same period last year[88]. - The company reported a significant increase in research and development expenses, totaling ¥185,278,131.46, up 12.39% from ¥164,852,509.26 year-on-year[88]. - The company’s investment income amounted to ¥421,617,643.54, accounting for 32.61% of total profit, indicating a stable income source from joint ventures[94]. - The company’s foreign sales increased by 54.00% to ¥2,856,344,679.36, while domestic sales slightly decreased by 1.27% to ¥3,843,318,755.65[89]. Strategic Developments - The company plans not to distribute cash dividends or issue bonus shares[7]. - Future plans and strategic developments are subject to market risks and do not constitute a commitment to investors[6]. - The company is actively expanding its pharmaceutical retail market while maintaining its leading position in the prescription market[39]. - The company is focused on enhancing its integrated production of raw materials and formulations, ensuring a stable supply of core products[43]. - The company is actively promoting its products through multiple channels, including pharmacies and e-commerce platforms[47]. - The company will continue to focus on academic marketing and professional promotion to expand market coverage and build an efficient marketing model in response to the significant policy changes regarding essential medicines[118]. - The company is actively exploring the outpatient retail market to increase its market share outside of hospital prescription drugs, addressing the risks of price reductions due to centralized procurement of generic drugs[118]. Product Development and Innovation - The company launched multiple functional skincare products in the first half of 2022, further enriching its product matrix in the skin health management sector[39]. - The company has expanded its product offerings in dermatology, tuberculosis, and oncology, launching multiple new products in the first half of the year, including various skincare and acne treatment products[47]. - The company has developed two Class 1 new drugs and over 20 generic drugs, with 180 patents granted, showcasing its strong innovation capabilities in the pharmaceutical sector[72]. - The company has a strong R&D team with 176 technical personnel, including 4 PhDs and 6 Master's degrees, focusing on high-end chemical products and high-performance polymer materials[67]. - The company holds 137 valid patents, including 86 invention patents, and has established partnerships with universities and research institutions to enhance innovation[67]. Market Presence and Expansion - The company has covered over 200,000 terminal points in the market by expanding into county-level, grassroots, and clinic channels, enhancing its presence in the outpatient market[50]. - The company has established partnerships with over 10 online platforms, including Alibaba Health and Meituan, to enhance its e-commerce presence[50]. - The company has formed stable strategic partnerships with international agricultural chemical companies, ensuring smooth sales channels and enhancing market presence[81]. - The company has built a solid customer base with recognized product quality and stable supply capabilities, serving markets in China, Japan, South Korea, and the United States[83]. Environmental and Safety Management - The company is committed to safety management and compliance with national safety production laws to prevent accidents in its production processes[124]. - The company has established a comprehensive safety production responsibility system and management framework, ensuring effective implementation of safety protocols[200]. - The company has implemented strict pollution discharge standards, ensuring compliance with environmental regulations[140]. - The company has established an environmental monitoring plan, with all monitoring results meeting national standards, and has publicly disclosed this information[190]. - The company has engaged third-party monitoring agencies to ensure compliance with environmental regulations, with all results published on relevant platforms[188]. - The company has implemented measures to manage foreign exchange risks, including regular price adjustments with clients and collaboration with financial institutions[123]. Social Responsibility - The company actively participated in social responsibility initiatives, with a total of 640,000 RMB spent on poverty alleviation and rural revitalization efforts[192]. - The company donated 1 million RMB to support local government pandemic prevention efforts and provided over 50,000 RMB worth of protective equipment and food[192]. Challenges and Risks - The company has faced significant impacts from uncontrollable events, such as major pandemics and natural disasters, and is implementing preventive measures to minimize these effects[129]. - The company will closely monitor the implementation of healthcare reform and regulatory policies, ensuring timely adjustments to its strategies in response to potential changes[119]. - The company has established a risk-oriented internal management system to enhance environmental protection research and development investments, addressing uncertainties in environmental policies[123].